TABLE 3.
Characteristic | No. | OR | 95% CI |
---|---|---|---|
Unilateral or partial oophorectomy (compared with no oophorectomy) | 961 | 1.50 | 1.02–2.21 |
Bilateral oophorectomy (compared with no oophorectomy) | 1.27 | 0.94–1.71 | |
1 y since hysterectomy | 1,006 | 0.99 | 0.97–1.01 |
1 y since bilateral oophorectomy | 353 | 1.01 | 0.98–1.04 |
1 y since hysterectomy without HT use | 1,006 | 0.99 | 0.98–1.01 |
1 y used HT before WHI enrollment | 1,006 | 1.00 | 0.97–1.03 |
<5 y used HT before WHI enrollment (compared with no previous HT use) | 1,006 | 1.01 | 0.74–1.39 |
5–10 y used HT before WHI enrollment (compared with no previous HT use) | 1.51 | 0.98–2.33 | |
>10 y used HT before WHI enrollment (compared with no previous HT use) | 0.91 | 0.59–1.40 |
Values adjusted for age at time of computed tomography scan, ethnicity, smoking, diabetes mellitus, hypertension, high cholesterol, body mass index, education, and conjugated equine estrogens trial randomization status. OR, odds ratio; HT, hormone therapy; WHI, Women’s Health Initiative.
Entire cohort except those with angioplasty or coronary artery bypass graft.